GlaxoSmithKline's Lamictal decreases seizures in adolescents, study says

By Elaine Rigoli

Tampa, Fla., Aug. 1 - Data published in the journal Pediatrics suggests that GlaxoSmithKline's lamotrigine (Lamictal) is an effective add-on therapy for the treatment of primary generalized tonic-clonic seizures in a subgroup of children and adolescents.

This randomized, double-blind clinical trial of primary generalized tonic-clonic seizures focused on patients between the ages of two and 20 and showed that Lamictal decreased seizures by 77% versus 40% in the placebo group.

The company said primary generalized tonic-clonic seizures, also known as "grand mal" seizures, are the most common form of generalized seizures, occurring in about 20% of patients with epilepsy. Lamictal is not currently indicated for the treatment of these seizures.

GlaxoSmithKline is a global pharmaceutical company based in London.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.